Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8078800 | 0.80 | — | — | |
| SCHEMBL5160223 | 0.77 | — | — | |
| SCHEMBL5163476 | 0.77 | — | — | |
| SCHEMBL4606229 | 0.77 | EPHX1 (0.39) | EPHX1 | |
| SCHEMBL2916248 | 0.76 | — | — | |
| SCHEMBL5008463 | 0.75 | GABRR1 (0.38) | — | |
| SCHEMBL5781533 | 0.74 | — | — | |
| SCHEMBL8913111 | 0.72 | — | — | |
| SCHEMBL3219647 | 0.72 | DPP4 (0.33) | — | |
| SCHEMBL1264064 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070117857-A1 | Substituted 3-amido-tetrahydro-indazolyl cannabinoid modulators | JANSSEN PHARMACEUTICA, N.V. | 2007-05-24 | — | — | US | claimed |
| US-20070117858-A1 | SUBSTITUTED 5-HETEROARYL-1-PHENYL-PYRAZOLE CANNABINOID MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-05-24 | — | — | US | claimed |
| US-8207156-B2 | Substituted pyrazoline compounds, their preparation and use as medicaments | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2012-06-26 | — | — | US | disclosed |
| US-20080306115-A1 | Midazole-4-Carboxamide Derivatives For Use As Cb1 Modulators | ASTRAZENECA AB (SE) | 2008-12-11 | — | — | US | disclosed |
| US-20080287517-A1 | Pyrazole Derivatives as Cb1 Modulators | ASTRAZENECA AB (SE) | 2008-11-20 | — | — | US | disclosed |
| EP-1966194-A2 | SUBSTITUTED 5-HETEROARYL-1-PHENYL-PYRAZOLE CANNABINOID MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-09-10 | — | — | EP | disclosed |
| EP-1940820-A1 | MIDAZOLE-4-CARBOXAMIDE DERIVATIVES FOR USE AS CB MODULATORS | AstraZeneca AB (SE) | 2008-07-09 | — | — | EP | disclosed |
| EP-1910302-A1 | CARBONYL SUBSTITUTED PYRAZOLINE COMPOUNDS, THEIR PREPARATION AND USE AS CB1 RECEPTOR MODULATORS | Laboratorios del Dr. Esteve S.A. (ES) | 2008-04-16 | — | — | EP | disclosed |
| EP-1804791-A1 | TETRAHYDRO PYRIDINYL PYRAZOLE CANNABINOID MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-07-11 | — | — | EP | disclosed |
| WO-2007061948-A2 | SUBSTITUTED 5-HETEROARYL-1-PHENYL-PYRAZOLE CANNABINOID MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-05-31 | — | — | WO | disclosed |
| US-20070117857-A1 | Substituted 3-amido-tetrahydro-indazolyl cannabinoid modulators | JANSSEN PHARMACEUTICA, N.V. | 2007-05-24 | — | — | US | disclosed |
| US-20070117858-A1 | SUBSTITUTED 5-HETEROARYL-1-PHENYL-PYRAZOLE CANNABINOID MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-05-24 | — | — | US | disclosed |
| WO-2007031721-A1 | MIDAZOLE-4-CARBOXAMIDE DERIVATIVES FOR USE AS CB MODULATORS | ASTRAZENECA AB (SE) | 2007-03-22 | — | — | WO | disclosed |
| WO-2007009687-A1 | CARBONYL SUBSTITUTED PYRAZOLINE COMPOUNDS, THEIR PREPARATION AND USE AS CB1 RECEPTOR MODULATORS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-01-25 | — | — | WO | disclosed |
| US-20070021398-A1 | Substituted Pyrazoline Compounds, their Preparation and Use as Medicaments | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-01-25 | — | — | US | disclosed |
| WO-2006049880-A1 | TETRAHYDRO PYRIDINYL PYRAZOLE CANNABINOID MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-05-11 | — | — | WO | disclosed |
| US-20060089378-A1 | Tetrahydro-pyridinyl pyrazole cannabinoid modulators | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306115-A1 | Midazole-4-Carboxamide Derivatives For Use As Cb1 Modulators | CNR2, CNR1, FAAH | EPHX1 1321/4885 |
| US-20080287517-A1 | Pyrazole Derivatives as Cb1 Modulators | CNR1, CNR2, HTR3C | EPHX1 638/4885 |
| US-20070117857-A1 | Substituted 3-amido-tetrahydro-indazolyl cannabinoid modulators | CNR2, CNR1, GPR18 | EPHX1 1263/4885 |
| US-20060089378-A1 | Tetrahydro-pyridinyl pyrazole cannabinoid modulators | CNR2, CNR1, GPR18 | EPHX1 774/4885 |
| US-20070021398-A1 | Substituted Pyrazoline Compounds, their Preparation and Use as Medicaments | PIR, SYMPK, P2RX5 | EPHX1 3499/4885 |
| US-20070117858-A1 | SUBSTITUTED 5-HETEROARYL-1-PHENYL-PYRAZOLE CANNABINOID MODULATORS | CNR1, CNR2, GPR18 | EPHX1 914/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.